VisMederi srl
VisMederi is a company specializing in vaccine assessment, bioanalytical services, diagnostic testing, and research collaborations. It is committed to quality, innovation, and international excellence in the field of life sciences and public health, with a focus on vaccine development, evaluation, and research on infectious diseases including COVID-19. The company aims to contribute to the improvement of the Public Health System through methods of analysis and evaluation of vaccine, drug, and molecule efficacy for therapeutic purposes, guided by values of quality and expertise. Its mission is to develop better and safer medicines and vaccines, providing qualified services and analytical data to pharmaceutical companies, aspiring to become a leader in the vaccine field.
Industries
Nr. of Employees
small (1-50)
VisMederi srl
Via Franco Ferrini 53, Loc. Tognazza – San Martino, 53035 Monteriggioni – Siena, Italy
Products
Needle-free SARS-CoV-2 vaccine candidate (collaborative development)
A collaborative vaccine development project producing a SARS-CoV-2 vaccine candidate designed for needle-free administration (reported as a candidate product developed with an academic partner).
Needle-free SARS-CoV-2 vaccine candidate (collaborative development)
A collaborative vaccine development project producing a SARS-CoV-2 vaccine candidate designed for needle-free administration (reported as a candidate product developed with an academic partner).
Services
Creation, optimization and standardization of microbiological, serological and virological assays to assess immunogenicity and support epidemiological screening and diagnostic evaluation.
Operational project management and coordination services for clinical development programs, with integration between study oversight and laboratory testing.
Development and performance assessment of immuno-enzymatic diagnostic tests and related evaluations to support diagnostic product development.
Comprehensive testing services for vaccine studies, including binding antibody assays, neutralization testing (live and pseudoparticle), cellular immunity assays and molecular detection.
In-house cell culture capabilities and laboratory support to enable virology, immunology and assay development workflows.
Calibration, adjustment and maintenance services for laboratory volume instruments such as micropipettes and dispensers, provided via an affiliated calibration entity.
Creation, optimization and standardization of microbiological, serological and virological assays to assess immunogenicity and support epidemiological screening and diagnostic evaluation.
Operational project management and coordination services for clinical development programs, with integration between study oversight and laboratory testing.
Development and performance assessment of immuno-enzymatic diagnostic tests and related evaluations to support diagnostic product development.
Comprehensive testing services for vaccine studies, including binding antibody assays, neutralization testing (live and pseudoparticle), cellular immunity assays and molecular detection.
In-house cell culture capabilities and laboratory support to enable virology, immunology and assay development workflows.
Calibration, adjustment and maintenance services for laboratory volume instruments such as micropipettes and dispensers, provided via an affiliated calibration entity.
Expertise Areas
- Vaccine immunogenicity assessment
- Serology and virology assay development
- Molecular diagnostics and pathogen detection
- Clinical trial management and study coordination
Key Technologies
- Enzyme-linked immunosorbent assay (ELISA)
- Haemagglutination inhibition (HAI)
- Single radial haemolysis (SRH)
- Microneutralization assays
News & Updates
In 2014, VisMederi obtained positive results, demonstrating its international competitiveness in life sciences services.
Recognition of VisMederi as an innovative start-up in Italy, featured in the publication l’Espresso.
From Siena to international collaborations, VisMederi is recognized as a local excellence with global impact.
The partnership between VisMederi and Emma Villas Siena, a volleyball team in Serie A2, is renewed for the third consecutive year, emphasizing local success and collaboration.
VisMederi announced its new corporate structure involving the sale of shares to Prof. Emanuele Montomoli.
VisMederi announced a new collaboration with Eurocine Vaccines, expanding its research and development partnerships.
In 2014, VisMederi obtained positive results, demonstrating its international competitiveness in life sciences services.
Recognition of VisMederi as an innovative start-up in Italy, featured in the publication l’Espresso.
From Siena to international collaborations, VisMederi is recognized as a local excellence with global impact.
The partnership between VisMederi and Emma Villas Siena, a volleyball team in Serie A2, is renewed for the third consecutive year, emphasizing local success and collaboration.
VisMederi announced its new corporate structure involving the sale of shares to Prof. Emanuele Montomoli.
VisMederi announced a new collaboration with Eurocine Vaccines, expanding its research and development partnerships.